EP1109582A4 - Technique propre a accentuer et a confiner l'expression de genes - Google Patents

Technique propre a accentuer et a confiner l'expression de genes

Info

Publication number
EP1109582A4
EP1109582A4 EP99943819A EP99943819A EP1109582A4 EP 1109582 A4 EP1109582 A4 EP 1109582A4 EP 99943819 A EP99943819 A EP 99943819A EP 99943819 A EP99943819 A EP 99943819A EP 1109582 A4 EP1109582 A4 EP 1109582A4
Authority
EP
European Patent Office
Prior art keywords
genes
enhance
methods
confine
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99943819A
Other languages
German (de)
English (en)
Other versions
EP1109582A1 (fr
Inventor
Yuen Kai Fung
Charles Gomer
Ang Anne T
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of EP1109582A1 publication Critical patent/EP1109582A1/fr
Publication of EP1109582A4 publication Critical patent/EP1109582A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/008Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/20Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP99943819A 1998-08-18 1999-08-18 Technique propre a accentuer et a confiner l'expression de genes Withdrawn EP1109582A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9694798P 1998-08-18 1998-08-18
US96947P 1998-08-18
PCT/US1999/019095 WO2000010612A1 (fr) 1998-08-18 1999-08-18 Technique propre a accentuer et a confiner l'expression de genes

Publications (2)

Publication Number Publication Date
EP1109582A1 EP1109582A1 (fr) 2001-06-27
EP1109582A4 true EP1109582A4 (fr) 2004-11-03

Family

ID=22259886

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99943819A Withdrawn EP1109582A4 (fr) 1998-08-18 1999-08-18 Technique propre a accentuer et a confiner l'expression de genes

Country Status (11)

Country Link
EP (1) EP1109582A4 (fr)
JP (1) JP2002523032A (fr)
KR (1) KR20020013463A (fr)
CN (1) CN1321093A (fr)
AU (1) AU763183B2 (fr)
CA (1) CA2340929A1 (fr)
IL (1) IL141473A0 (fr)
NZ (1) NZ509966A (fr)
RU (1) RU2226108C2 (fr)
WO (1) WO2000010612A1 (fr)
ZA (1) ZA200101207B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060105458A1 (en) * 2002-08-09 2006-05-18 Sidney Cambridge Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression
KR20030019282A (ko) * 2002-11-27 2003-03-06 김상태 βAPP의 C말단 pCT105 원격제어에 의한 치매발병 유도 세포주 개발
CA2600882C (fr) 2005-03-16 2013-02-26 Metabolix, Inc. Expression inductible chimiquement de voies biosynthetiques
JP2014503173A (ja) * 2009-11-05 2014-02-13 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ 制御された発現系
CN101892256B (zh) * 2010-01-27 2012-05-09 中国农业科学院北京畜牧兽医研究所 一种培育猪生长激素表达量增强的转基因动物的方法
CA2844283C (fr) 2011-08-08 2024-06-04 Curelab Oncology, Inc. Methodes et compositions associees a p62 pour le traitement et la prophylaxie du cancer
CN102786599B (zh) * 2012-08-01 2014-01-15 中国农业科学院作物科学研究所 水稻转录因子Os05g39950基因的应用
SG11201605316VA (en) 2013-12-29 2016-07-28 Curelab Oncology Inc Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
CN105925609B (zh) * 2016-07-14 2019-01-08 中国医学科学院输血研究所 带有标记基因的Tet-on诱导过表达的重组载体及构建方法
CN110016464A (zh) * 2018-01-08 2019-07-16 张晋宇 用于筛选抗肿瘤物质的系统及方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027021A1 (fr) * 1995-03-01 1996-09-06 Cornell Research Foundation, Inc. Vecteurs d'adenovirus interdependants et leurs procedes d'utilisation
WO1998006864A2 (fr) * 1996-08-15 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Regulation spatiale et temporelle de l'expression genique au moyen d'un promoteur proteique du stress associe a une source de chaleur locale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891718A (en) * 1996-03-27 1999-04-06 Vical Incorporated Tetracycline inducible/repressible systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996027021A1 (fr) * 1995-03-01 1996-09-06 Cornell Research Foundation, Inc. Vecteurs d'adenovirus interdependants et leurs procedes d'utilisation
WO1998006864A2 (fr) * 1996-08-15 1998-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Regulation spatiale et temporelle de l'expression genique au moyen d'un promoteur proteique du stress associe a une source de chaleur locale

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HALLAHAN D E ET AL: "SPATIAL AND TEMPORAL CONTROL OF GENE THERAPY USING IONIZING RADIATION", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 1, no. 8, August 1995 (1995-08-01), pages 786 - 791, XP000857200, ISSN: 1078-8956 *
MAUCERI H J ET AL: "TUMOR NECROSIS FACTOR ALPHA(TNT-ALPHA) GENE THERAPY TARGETED BY IONIZING RADIATION SELECTIVELY DAMAGES TUMOR VASCULATURE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, 1996, pages 4311 - 4314, XP002936211, ISSN: 0008-5472 *
See also references of WO0010612A1 *
WEICHSELBAUM R R ET AL: "GENE THERAPY TARGETED BY RADIATION PREFERENTIALLY RADIOSENSITIZES TUMOR CELLS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, 15 August 1994 (1994-08-15), pages 4266 - 4269, XP002932030, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
KR20020013463A (ko) 2002-02-20
CA2340929A1 (fr) 2000-03-02
IL141473A0 (en) 2002-03-10
WO2000010612A1 (fr) 2000-03-02
AU5684599A (en) 2000-03-14
AU763183B2 (en) 2003-07-17
EP1109582A1 (fr) 2001-06-27
CN1321093A (zh) 2001-11-07
RU2226108C2 (ru) 2004-03-27
NZ509966A (en) 2003-07-25
ZA200101207B (en) 2007-01-31
JP2002523032A (ja) 2002-07-30

Similar Documents

Publication Publication Date Title
PL316200A1 (en) Co-ordinated expression of genes in vivo
IL138191A0 (en) Expression of trehalose biosynthetic genes in plants
PL340760A1 (en) Genes of desaturase and their application
HUP0103329A3 (en) Expression and export of angiostatin and endostatin as immunofusis
HUP0200773A3 (en) Methods of inducing cacer cell death and tumor regression
IL131486A0 (en) Gene sequencer and methods
AP2000001762A0 (en) Method of delivering genes to antigen presenting cells of the skin
AU2001292842A1 (en) Compositions and methods relating to prostate specific genes and proteins
GB9706381D0 (en) Improvements relating to the specificity of gene expression
EP1109582A4 (fr) Technique propre a accentuer et a confiner l'expression de genes
GB9819898D0 (en) New vaccine and method of use
AU2002245031A1 (en) Compositions and methods relating to prostate specific genes and proteins
PL352326A1 (en) Noval vegetable genes and use of same
HUP0204093A3 (en) Sorghum dwarfing genes and methods of use
AU2584699A (en) Immediate early genes and methods of use therefor
AU9221098A (en) Selective expression of genes in plants
AU2002217991A1 (en) Compositions and methods relating to prostate specific genes and proteins
GB9721075D0 (en) Materials and methods relating to the stimulation of cells
AU1576501A (en) Methods to enhance and confine gene expression in cancer therapy
GB9904802D0 (en) Improvements in or relating to an item of headgear
AU2002241557A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU2002236579A1 (en) Compositions and methods relating to prostate specific genes and proteins
SG87764A1 (en) Methods of layering cache and architectural specific functions to expediate multiple designs
AU6387699A (en) Rac-like genes and methods of use
EP1210111A4 (fr) Adn de l'herpesvirus gamma et ses procedes d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040921

17Q First examination report despatched

Effective date: 20050421

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051103